Articles Posted in Product Liability

Folks who are regular readers of my blog, have seen the articles I have written about regarding DePuy ASR Metal on Metal hips. Unfortunately, despite my best efforts to highlight this tragedy, we still get inquiries from potential clients who are unaware and uninformed about the dangers of metallosis.

We should be shocked at the intolerable and unacceptable suffering caused to thousands of patients fitted with faulty DePuy hip implants and we should demand urgent action from DePuy.

Many of the 96,000 Americans who had received the DePuy metal-on-metal hip replacements, unfortunately need one or more revision surgeries and they also report serious and systemic health problems extending beyond the initial complications caused by the device.

Effective today, the diabetes drug Avandia will only be available through certified mail-order pharmacies. These new restrictions are designed to limit the number of people exposed to potential heart side effects of Avandia.

The FDA allowed Avandia to remain on the market last year, subject to a new risk evaluation and mitigation strategy (REMS). This special program limits sales of the medication to mail order and requires educational programs before it can be prescribed.

Today, is the last day Avandia will be available on retail pharmacy shelves. To continue receiving the medication after this week, healthcare providers and patients must enroll in the Avandia-Rosiglitazone Medicines Access Program.

Not a day goes by, before more bad news regarding the DePuy ASR and Pinnacle Hip Replacement and Recall issue percolates to the surface. As folks who have been following this story, the DePuy saga continues unabated. This week, our firm filed 3 DePuy ASR lawsuits, in the federal court MDL in Ohio. This is the federal court where the federal filed cases have been consolidated, for pretrial workup. And we are evaluating many more cases of DePuy ASR failures and metallosis.

On a more interesting note, this month Johnson & Johnson’s Third Quarter Earnings Report was published. The quarterly earnings report outlines the various legal proceedings the Company is currently defending.

The report states that “[m]ultiple products of the Company’s subsidiaries are subject to product liability claims and lawsuits in which claimants seek substantial compensatory and, where available, punitive damages.” This material appears on page 18 of the 10K Report.

Our DePuy ASR Recall and Metallosis team, has been aggressively notifying the general public about the problems and risks associated with the Metal on Metal hips. As explained in the 30 plus articles that I have written, this is a huge problem and that we may be experiencing the tip of the litigation iceberg.

We can report with confidence that the federal ASR hip replacement lawsuits are increasing on a daily basis, as the knowledge of premature failure and the risks of metallosis, are being brought to the attention of the folks who underwent hip relacement with this type of hip model.

We get electronic notification each time a new DePuy ASR lawsuit is filed in the federal court overseeing this litigation. And our email box has been filling up with these notifications. There is an average of 20 new cases filed daily in the federal multidistrict litigation, In re: DePuy Orthopaedics, Inc. ASR Hip Implant Products Liability Litigation (“MDL No. 2197”).

Dr Shezad Malik Law Firm is writing this open letter to the FDA. We are requesting the U.S. Food & Drug Administration (FDA) to complete its ongoing safety review of Yaz, Yasmin and other birth control pills containing the synthetic progestin, drospirenone, as soon as possible.

Watch a tv video interview I did regarding one of my seriously injured Yaz client.

Recently, a FDA-funded study confirmed that women who use such birth control pills have an increased risk of blood clots (known as venous thrombosis) when compared to women using other hormonal contraceptives made with an older progestin called levonorgestrel.

I am writing this Actos update, regarding the Actos dangerous drug cancer side effects.

Actos (pioglitazone) is a medication manufactured and sold by Takeda Pharmaceuticals for treatment of Type 2 diabetes. The drug is part of the same class of medications as Avandia (rosiglitazone), which has been linked to an increased risk of heart attacks.

What is Actos?